Abstract
Controversy over the role of antioxidants in cancer has persisted for decades. Here, we demonstrate that synthesis of the antioxidant glutathione (GSH), driven by GCLM, is required for cancer initiation. Genetic loss of Gclm prevents a tumor's ability to drive malignant transformation. Intriguingly, these findings canbe replicated using an inhibitor of GSH synthesis, but only if delivered prior to cancer onset, suggesting that at later stages of tumor progression GSH becomes dispensable potentially due to compensation from alternative antioxidant pathways. Remarkably, combined inhibition of GSH and thioredoxin antioxidant pathways leads to a synergistic cancer cell death invitro and invivo, demonstrating theimportance of these two antioxidants to tumor progression and as potential targets for therapeutic intervention.
Original language | English |
---|---|
Pages (from-to) | 211-222 |
Number of pages | 12 |
Journal | Cancer Cell |
Volume | 27 |
Issue number | 2 |
DOIs | |
Publication status | Published - 9 Feb 2015 |
Externally published | Yes |